Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 166Triple Negative Breast Neoplasms 54Neoplasm Metastasis 23Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 15Ovarian Neoplasms 11Colorectal Neoplasms 9Small Cell Lung Carcinoma 8Sarcoma 8Neoplasms 8Lung Neoplasms 8Prostatic Neoplasms 7Colonic Neoplasms 7Breast Neoplasms, Male 7Stomach Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Recurrence 3Rectal Neoplasms 3Multiple Myeloma 3Melanoma 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Endometrial Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2

Interventions

capivasertib 2tremelimumab 1grapiprant 1durvalumab 1Standard of Care 1Practice Guidelines as Topic 1Palliative Care 1Gemcitabine 1Fulvestrant 1Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × Gemcitabine × Breast × Clear all
NCT02538432 2019-11-04

Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors

University of Maryland, Baltimore

Phase 2 Withdrawn
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡